OKYO vs DTCX Comparison

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Datacentrex Inc is a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses. Its current operating platform is centered on owned and operated Scrypt-based proof-of-work compute deployed through third-party colocation facilities. Datacentrex monetizes this compute through hashrate marketplace mechanisms and manages a treasury of digital assets and cash in a manner intended to preserve capital and support opportunistic, accretive deployment. The company's operations are principally operated remotely at various data centers throughout the United States.